Bergen, Norway, 29 June 2021?- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, today announces that its late-breaking abstract,
outlining Phase II clinical trial of bemcentinib, a first-in-class selective
oral AXL inhibitor, in hospitalised COVID-19 patients has been published at the
European Congress of Clinical Microbiology & Infectious Diseases (ECCMID),
taking place online from 9-12 July 2021.

The abstract outlines data from two randomised, open-label Phase II studies in
South Africa and India (BGBC020) and the UK (ACCORD2). 177 eligible patients
were enrolled across 3 countries in both studies between May 2020 and March 2021
in bemcentinib and SOC arms. Results showed that from baseline to day 29, there
were fewer deaths in the bemcentinib treated patients (2 of 58 and 1 of 28)
versus SOC (3 of 57 and 5 of 32) for BGBC020 and ACCORD2 respectively.
Bemcentinib was well tolerated throughout both studies.

These exploratory studies demonstrate encouraging evidence for the effect of
bemcentinib in hospitalised COVID-19 patients receiving steroids ± remdesivir.
Bemcentinib is an orally administered, well-tolerated AXL kinase inhibitor which
targets a host receptor to achieve antiviral effects